A Sex-Dependent Association Between Doxycycline Use and Development of Schizophrenia.
doxycycline
observational study
schizophrenia
tetracycline antibiotics
Journal
Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760
Informations de publication
Date de publication:
04 07 2023
04 07 2023
Historique:
pmc-release:
03
03
2024
medline:
6
7
2023
pubmed:
5
3
2023
entrez:
4
3
2023
Statut:
ppublish
Résumé
Doxycycline and minocycline are brain-penetrant tetracycline antibiotics, which recently gained interest because of their immunomodulatory and neuroprotective properties. Observational studies have suggested that exposure to these drugs may decrease the risk to develop schizophrenia, but results are inconsistent. The aim of this study was to investigate the potential association between doxycycline use and later onset of schizophrenia. We used data from 1 647 298 individuals born between 1980 and 2006 available through Danish population registers. 79 078 of those individuals were exposed to doxycycline, defined as redemption of at least 1 prescription. Survival analysis models stratified for sex with time-varying covariates were constructed to assess incidence rate ratios (IRRs) for schizophrenia (ICD-10 code F20.xx), with adjustment for age, calendar year, parental psychiatric status, and educational level. In the non-stratified analysis, there was no association between doxycycline exposure and schizophrenia risk. However, men who redeemed doxycycline had a significantly lower incidence rate for schizophrenia onset compared to men that did not (IRR 0.70; 95% CI 0.57-0.86). By contrast, women had a significantly higher incidence rate for schizophrenia onset, compared to women that did not redeem doxycycline prescriptions (IRR 1.23; 95% CI 1.08, 1.40). The effects were not found for other tetracycline antibiotics (IRR 1.00; 95% CI 0.91, 1.09). Doxycycline exposure is associated with a sex-dependent effect on schizophrenia risk. The next steps are replication of the results in independent well-characterized population cohorts, as well as preclinical studies to investigate sex-specific effects of doxycycline on biological mechanisms implicated in schizophrenia.
Sections du résumé
BACKGROUND
Doxycycline and minocycline are brain-penetrant tetracycline antibiotics, which recently gained interest because of their immunomodulatory and neuroprotective properties. Observational studies have suggested that exposure to these drugs may decrease the risk to develop schizophrenia, but results are inconsistent. The aim of this study was to investigate the potential association between doxycycline use and later onset of schizophrenia.
DESIGN
We used data from 1 647 298 individuals born between 1980 and 2006 available through Danish population registers. 79 078 of those individuals were exposed to doxycycline, defined as redemption of at least 1 prescription. Survival analysis models stratified for sex with time-varying covariates were constructed to assess incidence rate ratios (IRRs) for schizophrenia (ICD-10 code F20.xx), with adjustment for age, calendar year, parental psychiatric status, and educational level.
RESULTS
In the non-stratified analysis, there was no association between doxycycline exposure and schizophrenia risk. However, men who redeemed doxycycline had a significantly lower incidence rate for schizophrenia onset compared to men that did not (IRR 0.70; 95% CI 0.57-0.86). By contrast, women had a significantly higher incidence rate for schizophrenia onset, compared to women that did not redeem doxycycline prescriptions (IRR 1.23; 95% CI 1.08, 1.40). The effects were not found for other tetracycline antibiotics (IRR 1.00; 95% CI 0.91, 1.09).
CONCLUSIONS
Doxycycline exposure is associated with a sex-dependent effect on schizophrenia risk. The next steps are replication of the results in independent well-characterized population cohorts, as well as preclinical studies to investigate sex-specific effects of doxycycline on biological mechanisms implicated in schizophrenia.
Identifiants
pubmed: 36869773
pii: 7069253
doi: 10.1093/schbul/sbad008
pmc: PMC10318877
doi:
Substances chimiques
Doxycycline
N12000U13O
Minocycline
FYY3R43WGO
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
953-961Subventions
Organisme : NIMH NIH HHS
ID : R21 MH123913
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Int Rev Psychiatry. 2010;22(5):417-28
pubmed: 21047156
Neurotox Res. 2016 Oct;30(3):285-94
pubmed: 27342132
J Neural Transm (Vienna). 2018 Oct;125(10):1403-1415
pubmed: 30109452
Soc Psychiatry Psychiatr Epidemiol. 2009 Apr;44(4):265-71
pubmed: 18836884
Schizophr Bull. 2013 Sep;39(5):1129-38
pubmed: 23042112
Neuron. 2019 Apr 17;102(2):435-449.e6
pubmed: 30827729
Nature. 2016 Feb 11;530(7589):177-83
pubmed: 26814963
Lancet. 2013 Apr 20;381(9875):1371-1379
pubmed: 23453885
J Psychosom Res. 2019 Jun;121:60-67
pubmed: 31023486
Scand J Public Health. 2011 Jul;39(7 Suppl):38-41
pubmed: 21775349
Neurotox Res. 2016 May;29(4):447-59
pubmed: 26745968
Brain Behav Immun. 2023 Jan;107:305-318
pubmed: 36332817
Scand J Public Health. 2011 Jul;39(7 Suppl):95-8
pubmed: 21775363
Nat Neurosci. 2021 Jun;24(6):799-809
pubmed: 33958802
Nature. 2020 Jun;582(7813):577-581
pubmed: 32499649
Transl Psychiatry. 2021 Sep 8;11(1):468
pubmed: 34497261
Epidemiol Rev. 2008;30:67-76
pubmed: 18480098
Psychiatry J. 2019 Apr 16;2019:9804836
pubmed: 31139639
Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48
pubmed: 20592239
Psychiatry Res. 2013 Nov 30;210(1):8-15
pubmed: 23790604
Mol Psychiatry. 2018 May;23(5):1287-1292
pubmed: 28115737
Behav Pharmacol. 2021 Apr 1;32(2&3):123-141
pubmed: 33595954
JAMA Psychiatry. 2014 May;71(5):573-81
pubmed: 24806211
Schizophr Res. 2020 Jun;220:123-129
pubmed: 32299717
N Engl J Med. 1999 Feb 25;340(8):603-8
pubmed: 10029644
Annu Rev Neurosci. 2012;35:369-89
pubmed: 22715882
Psychol Med. 2022 Jul;52(9):1612-1620
pubmed: 35582864
J Neuroinflammation. 2020 Feb 15;17(1):56
pubmed: 32061259
J Psychiatr Res. 1982-1983;17(4):319-34
pubmed: 7187776
Nat Neurosci. 2019 Mar;22(3):374-385
pubmed: 30718903
Science. 2018 Feb 9;359(6376):693-697
pubmed: 29439242
Schizophr Bull. 2011 Jul;37(4):664-70
pubmed: 21602306
CNS Neurol Disord Drug Targets. 2009 Jun;8(3):222-31
pubmed: 19601819
Glia. 2020 Jun;68(6):1085-1099
pubmed: 31743527
Br J Pharmacol. 2013 May;169(2):337-52
pubmed: 23441623
J Psychopharmacol. 2018 May;32(5):559-568
pubmed: 29215319
Glia. 2021 May;69(5):1251-1267
pubmed: 33410555
Transl Psychiatry. 2017 Jun 20;7(6):e1155
pubmed: 28632202
Scand J Public Health. 2011 Jul;39(7 Suppl):54-7
pubmed: 21775352
Schizophr Bull. 2020 Feb 26;46(2):374-386
pubmed: 31192350
J Clin Med. 2018 Nov 27;7(12):
pubmed: 30486356
Scand J Public Health. 2011 Jul;39(7 Suppl):22-5
pubmed: 21775345
Transl Psychiatry. 2017 May 9;7(5):e1120
pubmed: 28485733
Clin Microbiol Rev. 2010 Oct;23(4):858-83
pubmed: 20930076
Acta Psychiatr Scand. 2013 Jan;127(1):62-8
pubmed: 22906158
Biol Psychiatry. 2022 Jan 1;91(1):102-117
pubmed: 34099189
Schizophr Bull. 2018 Aug 20;44(5):973-982
pubmed: 29648618
Stat Med. 2013 Dec 30;32(30):5315-27
pubmed: 24027131
Schizophr Res Treatment. 2012;2012:916198
pubmed: 22966451
Arch Gen Psychiatry. 2000 Jul;57(7):637-48
pubmed: 10891034
Neuron. 2012 May 24;74(4):691-705
pubmed: 22632727
Schizophr Res. 2012 Aug;139(1-3):161-8
pubmed: 22704639
Front Immunol. 2019 May 09;10:1076
pubmed: 31156632
NPJ Schizophr. 2020 May 1;6(1):12
pubmed: 32358572